Gou M, et al. - In order to improve effectiveness and survival, researchers evaluated the effectiveness and safety of nivolumab for metastatic biliary tract cancer (mBTC). At the People’s Liberation Army General Hospital, 30 patients with mBTC were voluntarily treated with nivolumab; for this investigation, nivolumab 3 mg/kg was used. Findings suggested that nivolumab safety in mBTC is can be managed. Fatigue, fever, hypothyroidism, skin reaction, and liver injury were the adverse events (AEs) of nivolumab monotherapy. The sole independent factor for longer progression-free survival was nivolumab in combination with chemotherapy.